

Care pathways


**38,604 people**

were diagnosed with bowel cancer in England and Wales between 1 April 2022 and 31 March 2023.

Proportion of people who presented with stage 1 or stage 2 cancer




Number of patients who presented with colorectal cancer by route of diagnosis\*




\*Data were impacted by the COVID-19 pandemic


Proportion of people recorded as being seen by a clinical nurse specialist (CNS)




Proportion of people in England with mismatch repair (MMR) immunohistochemistry test




Peri-operative care




% of people who died within 90 days of surgery



% of people with an unplanned 30-day return to theatre after surgery




% of people with an unclosed diverting ileostomy 18-months after anterior resection (major rectal cancer operation, year of surgery)



% of people with an unplanned 30-day readmission after surgery



% of trusts/MDTs that performed ≥ 20 major rectal cancer operations per year (year of surgery)



% of people who underwent major colorectal cancer surgery with a minimally invasive approach


Oncological management




% of people who received adjuvant chemotherapy for stage 3 colon cancer (year of surgery)



% of people who experienced severe acute toxicity after adjuvant chemotherapy (year of surgery)



% of people with rectal cancer who received neo-adjuvant radiotherapy treatment (year of diagnosis)



% of people alive 2-years after major colorectal cancer surgery (year of surgery)